A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
← catalyst calendarNCT06389136 · readout ≤ 12 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
200estimated
Sites
128
Countries
Canada, Colombia, Italy +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-14 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Interventions
- Drug: Upadacitinib 15mg Dose — also filed as ABT-494, RINVOQ
- Drug: Dupilumab 300mg Dose
- Drug: Upadacitinib 30mg Dose — also filed as ABT-494, RINVOQ
Primary outcome
what the primary-completion date above is the date OFParticipants who achieve at least a 90% reduction in Eczema Area and Severity Index from Baseline (EASI 90)
measured At Week 8
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed